ID   SPEG_HUMAN              Reviewed;        3267 AA.
AC   Q15772; A8K0G6; A8MRU0; Q27J74; Q695L1; Q6FGA6; Q6ZQW1; Q6ZTL8; Q9P2P9;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 4.
DT   12-OCT-2022, entry version 194.
DE   RecName: Full=Striated muscle preferentially expressed protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Aortic preferentially expressed protein 1;
DE            Short=APEG-1;
GN   Name=SPEG; Synonyms=APEG1, KIAA1297;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, SUBCELLULAR
RP   LOCATION, AND INDUCTION.
RX   PubMed=8663449; DOI=10.1074/jbc.271.29.17354;
RA   Hsieh C.-M., Yoshizumi M., Endege W.O., Kho C.-J., Jain M.K., Kashiki S.,
RA   de Los Santos R., Lee W.-S., Perrella M.A., Lee M.-E.;
RT   "APEG-1, a novel gene preferentially expressed in aortic smooth muscle
RT   cells, is down-regulated by vascular injury.";
RL   J. Biol. Chem. 271:17354-17359(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 12-129 (ISOFORM 1), AND ALTERNATIVE PROMOTER
RP   USAGE.
RX   PubMed=16545539; DOI=10.1016/j.ygeno.2006.01.009;
RA   Tam J.L.Y., Triantaphyllopoulos K., Todd H., Raguz S., de Wit T.,
RA   Morgan J.E., Partridge T.A., Makrinou E., Grosveld F., Antoniou M.;
RT   "The human desmin locus: gene organization and LCR-mediated transcriptional
RT   control.";
RL   Genomics 87:733-746(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 130-3267 (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT THR-2687.
RX   PubMed=15185077; DOI=10.1007/s00427-004-0413-5;
RA   Sutter S.B., Raeker M.O., Borisov A.B., Russell M.W.;
RT   "Orthologous relationship of obscurin and Unc-89: phylogeny of a novel
RT   family of tandem myosin light chain kinases.";
RL   Dev. Genes Evol. 214:352-359(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 982-3267 (ISOFORM 1), AND VARIANT
RP   THR-2687.
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-488, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (0.96 ANGSTROMS) OF 864-962, AND SUBUNIT.
RX   PubMed=16354304; DOI=10.1186/1472-6807-5-21;
RA   Manjasetty B.A., Niesen F.H., Scheich C., Roske Y., Goetz F., Behlke J.,
RA   Sievert V., Heinemann U., Bussow K.;
RT   "X-ray structure of engineered human aortic preferentially expressed
RT   protein-1 (APEG-1).";
RL   BMC Struct. Biol. 5:21-21(2005).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-206; CYS-934; GLN-966; LEU-1103;
RP   VAL-1135; ASP-1178; TRP-1234; GLN-1340; CYS-1621; TRP-1903; THR-2687;
RP   MET-2742 AND ARG-3079.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [13]
RP   INTERACTION WITH MTM1, INVOLVEMENT IN CNM5, AND VARIANT CNM5 VAL-2757.
RX   PubMed=25087613; DOI=10.1016/j.ajhg.2014.07.004;
RA   Agrawal P.B., Pierson C.R., Joshi M., Liu X., Ravenscroft G.,
RA   Moghadaszadeh B., Talabere T., Viola M., Swanson L.C., Haliloglu G.,
RA   Talim B., Yau K.S., Allcock R.J., Laing N.G., Perrella M.A., Beggs A.H.;
RT   "SPEG interacts with myotubularin, and its deficiency causes centronuclear
RT   myopathy with dilated cardiomyopathy.";
RL   Am. J. Hum. Genet. 95:218-226(2014).
CC   -!- FUNCTION: Isoform 3 may have a role in regulating the growth and
CC       differentiation of arterial smooth muscle cells.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- SUBUNIT: Interacts with MTM1. Isoform 3 is found as a monomer or
CC       homodimer. {ECO:0000269|PubMed:16354304, ECO:0000269|PubMed:25087613}.
CC   -!- INTERACTION:
CC       Q15772; Q99873: PRMT1; NbExp=3; IntAct=EBI-1384196, EBI-78738;
CC       Q15772-4; O75031: HSF2BP; NbExp=3; IntAct=EBI-12175897, EBI-7116203;
CC       Q15772-4; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-12175897, EBI-16439278;
CC       Q15772-4; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-12175897, EBI-79165;
CC       Q15772-4; Q99873-3: PRMT1; NbExp=3; IntAct=EBI-12175897, EBI-17165527;
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;
CC       Name=4;
CC         IsoId=Q15772-5; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15772-3; Sequence=VSP_018259, VSP_018261, VSP_018262;
CC       Name=3; Synonyms=APEG1;
CC         IsoId=Q15772-4; Sequence=VSP_018258, VSP_018261, VSP_018262;
CC       Name=1; Synonyms=SPEG;
CC         IsoId=Q15772-1; Sequence=VSP_036071;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is preferentially expressed in striated
CC       muscle. Non-kinase form such as isoform 3 is predominantly expressed in
CC       the aorta. Isoform 3 appears to be expressed only in highly
CC       differentiated ASMC in normal vessel walls and down-regulated in
CC       dedifferentiated ASMC in vivo. In response to vascular injuries ASMC
CC       dedifferentiate and change from a quiescent and contractile phenotype
CC       to a proliferative and synthetic phenotype. This proliferation of
CC       vascular smooth muscle cells is one of the most prominent features of
CC       atherosclerosis. {ECO:0000269|PubMed:15185077,
CC       ECO:0000269|PubMed:8663449}.
CC   -!- INDUCTION: Isoform 3 is quickly down-regulated in response to vascular
CC       injury, when ASMC cells change from a quiescent to a proliferative
CC       phenotype. {ECO:0000269|PubMed:8663449}.
CC   -!- PTM: May be autophosphorylated.
CC   -!- DISEASE: Myopathy, centronuclear, 5 (CNM5) [MIM:615959]: A form of
CC       centronuclear myopathy, a congenital muscle disorder characterized by
CC       progressive muscular weakness and wasting involving mainly limb girdle,
CC       trunk, and neck muscles. It may also affect distal muscles. Weakness
CC       may be present during childhood or adolescence or may not become
CC       evident until the third decade of life. Ptosis is a frequent clinical
CC       feature. The most prominent histopathologic features include high
CC       frequency of centrally located nuclei in muscle fibers not secondary to
CC       regeneration, radial arrangement of sarcoplasmic strands around the
CC       central nuclei, and predominance and hypotrophy of type 1 fibers. CNM5
CC       features include severe neonatal hypotonia with respiratory
CC       insufficiency, difficulty feeding, and delayed motor development. Some
CC       patients die in infancy, and some develop dilated cardiomyopathy.
CC       {ECO:0000269|PubMed:25087613}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Expression is under the tight control of the locus
CC       control region (LCRs).
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAY15052.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=ABD61734.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U57099; AAC50599.1; -; mRNA.
DR   EMBL; AK126500; BAC86568.1; -; mRNA.
DR   EMBL; AK289531; BAF82220.1; -; mRNA.
DR   EMBL; CR542201; CAG46998.1; -; mRNA.
DR   EMBL; AC053503; AAY15052.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471063; EAW70747.1; -; Genomic_DNA.
DR   EMBL; BC006346; AAH06346.1; -; mRNA.
DR   EMBL; DQ395348; ABD61734.1; ALT_FRAME; mRNA.
DR   EMBL; AY603755; AAT80901.1; -; mRNA.
DR   EMBL; AB037718; BAA92535.1; -; mRNA.
DR   CCDS; CCDS42824.1; -. [Q15772-5]
DR   CCDS; CCDS54432.1; -. [Q15772-4]
DR   RefSeq; NP_001166947.1; NM_001173476.1. [Q15772-4]
DR   RefSeq; NP_005867.3; NM_005876.4. [Q15772-5]
DR   RefSeq; XP_016858651.1; XM_017003162.1. [Q15772-3]
DR   PDB; 1U2H; X-ray; 0.96 A; A=864-960.
DR   PDBsum; 1U2H; -.
DR   SMR; Q15772; -.
DR   BioGRID; 115579; 14.
DR   IntAct; Q15772; 7.
DR   STRING; 9606.ENSP00000311684; -.
DR   GlyGen; Q15772; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q15772; -.
DR   PhosphoSitePlus; Q15772; -.
DR   BioMuta; SPEG; -.
DR   DMDM; 218512143; -.
DR   EPD; Q15772; -.
DR   jPOST; Q15772; -.
DR   MassIVE; Q15772; -.
DR   MaxQB; Q15772; -.
DR   PaxDb; Q15772; -.
DR   PeptideAtlas; Q15772; -.
DR   PRIDE; Q15772; -.
DR   ProteomicsDB; 60751; -. [Q15772-5]
DR   ProteomicsDB; 60752; -. [Q15772-1]
DR   ProteomicsDB; 60753; -. [Q15772-3]
DR   ProteomicsDB; 60754; -. [Q15772-4]
DR   Antibodypedia; 11575; 79 antibodies from 22 providers.
DR   DNASU; 10290; -.
DR   Ensembl; ENST00000312358.12; ENSP00000311684.7; ENSG00000072195.15. [Q15772-5]
DR   Ensembl; ENST00000396686.5; ENSP00000379917.1; ENSG00000072195.15. [Q15772-4]
DR   Ensembl; ENST00000396688.5; ENSP00000379919.1; ENSG00000072195.15. [Q15772-4]
DR   Ensembl; ENST00000396689.2; ENSP00000379920.2; ENSG00000072195.15. [Q15772-4]
DR   GeneID; 10290; -.
DR   KEGG; hsa:10290; -.
DR   MANE-Select; ENST00000312358.12; ENSP00000311684.7; NM_005876.5; NP_005867.3.
DR   UCSC; uc002vlq.4; human. [Q15772-5]
DR   CTD; 10290; -.
DR   DisGeNET; 10290; -.
DR   GeneCards; SPEG; -.
DR   HGNC; HGNC:16901; SPEG.
DR   HPA; ENSG00000072195; Tissue enhanced (intestine).
DR   MalaCards; SPEG; -.
DR   MIM; 615950; gene.
DR   MIM; 615959; phenotype.
DR   neXtProt; NX_Q15772; -.
DR   OpenTargets; ENSG00000072195; -.
DR   Orphanet; 169186; Autosomal recessive centronuclear myopathy.
DR   PharmGKB; PA142672598; -.
DR   VEuPathDB; HostDB:ENSG00000072195; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; KOG0613; Eukaryota.
DR   GeneTree; ENSGT00940000161126; -.
DR   HOGENOM; CLU_000381_0_0_1; -.
DR   InParanoid; Q15772; -.
DR   OrthoDB; 7796at2759; -.
DR   PhylomeDB; Q15772; -.
DR   TreeFam; TF331962; -.
DR   PathwayCommons; Q15772; -.
DR   SignaLink; Q15772; -.
DR   BioGRID-ORCS; 10290; 7 hits in 1088 CRISPR screens.
DR   ChiTaRS; SPEG; human.
DR   EvolutionaryTrace; Q15772; -.
DR   GeneWiki; SPEG; -.
DR   GenomeRNAi; 10290; -.
DR   Pharos; Q15772; Tbio.
DR   PRO; PR:Q15772; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q15772; protein.
DR   Bgee; ENSG00000072195; Expressed in popliteal artery and 169 other tissues.
DR   ExpressionAtlas; Q15772; baseline and differential.
DR   Genevisible; Q15772; HS.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0042692; P:muscle cell differentiation; IBA:GO_Central.
DR   GO; GO:0007517; P:muscle organ development; TAS:ProtInc.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 11.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015726; Ser/Thr_kin_striated-sp.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR47633:SF3; PTHR47633:SF3; 3.
DR   Pfam; PF07679; I-set; 9.
DR   Pfam; PF00069; Pkinase; 2.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00409; IG; 9.
DR   SMART; SM00408; IGc2; 9.
DR   SMART; SM00220; S_TKc; 2.
DR   SUPFAM; SSF48726; SSF48726; 9.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50835; IG_LIKE; 8.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   ATP-binding; Differentiation; Disease variant; Disulfide bond;
KW   Immunoglobulin domain; Kinase; Methylation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..3267
FT                   /note="Striated muscle preferentially expressed protein
FT                   kinase"
FT                   /id="PRO_0000072666"
FT   DOMAIN          43..124
FT                   /note="Ig-like 1"
FT   DOMAIN          722..810
FT                   /note="Ig-like 2"
FT   DOMAIN          869..958
FT                   /note="Ig-like 3"
FT   DOMAIN          963..1057
FT                   /note="Ig-like 4"
FT   DOMAIN          1064..1152
FT                   /note="Ig-like 5"
FT   DOMAIN          1188..1278
FT                   /note="Ig-like 6"
FT   DOMAIN          1285..1382
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1384..1480
FT                   /note="Ig-like 7"
FT   DOMAIN          1485..1573
FT                   /note="Ig-like 8"
FT   DOMAIN          1601..1854
FT                   /note="Protein kinase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          2583..2673
FT                   /note="Ig-like 9"
FT   DOMAIN          2680..2774
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2966..3218
FT                   /note="Protein kinase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..33
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          132..227
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          276..714
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          812..872
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1157..1180
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1906..2060
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2074..2239
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2253..2325
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2339..2399
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2411..2452
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2466..2564
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2771..2896
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2909..2966
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        157..199
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        295..331
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        340..359
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        361..381
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        402..418
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        471..487
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        495..516
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        538..556
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        585..599
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        661..683
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        812..828
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        848..868
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2164..2178
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2199..2237
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2353..2371
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2466..2481
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2512..2540
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2798..2828
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2882..2896
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2909..2927
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2928..2962
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1719
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        3085
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         1607..1615
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         1630
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         2972..2980
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         2995
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         364
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         371
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         375
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         378
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         381
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         449
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         453
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         488
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         506
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         526
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         549
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         1128
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         1172
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         1988
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2014
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2015
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2037
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2055
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2055
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2109
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2130
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2139
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2177
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2376
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2380
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2410
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2414
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2438
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2439
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2444
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2448
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2521
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2524
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2559
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2771
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   MOD_RES         2774
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63638"
FT   MOD_RES         2949
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62407"
FT   DISULFID        989..1041
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        2605..2657
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         1..849
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8663449, ECO:0000303|Ref.3"
FT                   /id="VSP_018258"
FT   VAR_SEQ         1..792
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_018259"
FT   VAR_SEQ         961..962
FT                   /note="AH -> GE (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449,
FT                   ECO:0000303|Ref.3"
FT                   /id="VSP_018261"
FT   VAR_SEQ         963..3267
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449,
FT                   ECO:0000303|Ref.3"
FT                   /id="VSP_018262"
FT   VAR_SEQ         3209..3267
FT                   /note="LQDCLAHPWLQDAYLMKLRRQTLTFTTNRLKEFLGEQRRRRAEAATRHKVLL
FT                   RSYPGGP -> SCLSVCHKEIKMASS (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:10718198,
FT                   ECO:0000303|PubMed:15185077, ECO:0000303|PubMed:16545539"
FT                   /id="VSP_036071"
FT   VARIANT         206
FT                   /note="R -> H (in dbSNP:rs55821435)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041101"
FT   VARIANT         934
FT                   /note="R -> C (in dbSNP:rs34398769)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041102"
FT   VARIANT         966
FT                   /note="R -> Q (in dbSNP:rs34861443)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041103"
FT   VARIANT         1103
FT                   /note="P -> L (in dbSNP:rs56334571)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041104"
FT   VARIANT         1135
FT                   /note="A -> V (in dbSNP:rs55670811)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041105"
FT   VARIANT         1178
FT                   /note="E -> D (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs757589345)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041106"
FT   VARIANT         1234
FT                   /note="R -> W (in dbSNP:rs55916864)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041107"
FT   VARIANT         1340
FT                   /note="R -> Q (in dbSNP:rs34994343)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041108"
FT   VARIANT         1621
FT                   /note="R -> C (in dbSNP:rs55646900)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041109"
FT   VARIANT         1903
FT                   /note="R -> W (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation; dbSNP:rs762000831)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041110"
FT   VARIANT         2189
FT                   /note="P -> L (in dbSNP:rs10755037)"
FT                   /id="VAR_059769"
FT   VARIANT         2687
FT                   /note="P -> T (in dbSNP:rs13026308)"
FT                   /evidence="ECO:0000269|PubMed:10718198,
FT                   ECO:0000269|PubMed:15185077, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041111"
FT   VARIANT         2742
FT                   /note="V -> M (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs566841339)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041112"
FT   VARIANT         2757
FT                   /note="G -> V (in CNM5; dbSNP:rs587777676)"
FT                   /evidence="ECO:0000269|PubMed:25087613"
FT                   /id="VAR_071808"
FT   VARIANT         3079
FT                   /note="H -> R (in dbSNP:rs12464085)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041113"
FT   CONFLICT        71
FT                   /note="Q -> H (in Ref. 7; ABD61734)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        73
FT                   /note="S -> I (in Ref. 7; ABD61734)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2047
FT                   /note="S -> G (in Ref. 8; AAT80901 and 9; BAA92535)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3005
FT                   /note="R -> P (in Ref. 8; AAT80901 and 9; BAA92535)"
FT                   /evidence="ECO:0000305"
FT   STRAND          867..873
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   STRAND          878..881
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   STRAND          886..896
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   STRAND          899..904
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   STRAND          915..919
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   HELIX           921..923
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   STRAND          924..931
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   HELIX           934..936
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   STRAND          938..946
FT                   /evidence="ECO:0007829|PDB:1U2H"
FT   STRAND          949..960
FT                   /evidence="ECO:0007829|PDB:1U2H"
SQ   SEQUENCE   3267 AA;  354289 MW;  E67BEB5624144233 CRC64;
     MQKARGTRGE DAGTRAPPSP GVPPKRAKVG AGGGAPVAVA GAPVFLRPLK NAAVCAGSDV
     RLRVVVSGTP QPSLRWFRDG QLLPAPAPEP SCLWLRRCGA QDAGVYSCMA QNERGRASCE
     AVLTVLEVGD SETAEDDISD VQGTQRLELR DDGAFSTPTG GSDTLVGTSL DTPPTSVTGT
     SEEQVSWWGS GQTVLEQEAG SGGGTRRLPG SPRQAQATGA GPRHLGVEPL VRASRANLVG
     ASWGSEDSLS VASDLYGSAF SLYRGRALSI HVSVPQSGLR REEPDLQPQL ASEAPRRPAQ
     PPPSKSALLP PPSPRVGKRS PPGPPAQPAA TPTSPHRRTQ EPVLPEDTTT EEKRGKKSKS
     SGPSLAGTAE SRPQTPLSEA SGRLSALGRS PRLVRAGSRI LDKLQFFEER RRSLERSDSP
     PAPLRPWVPL RKARSLEQPK SERGAPWGTP GASQEELRAP GSVAERRRLF QQKAASLDER
     TRQRSPASDL ELRFAQELGR IRRSTSREEL VRSHESLRAT LQRAPSPREP GEPPLFSRPS
     TPKTSRAVSP AAAQPPSPSS AEKPGDEPGR PRSRGPAGRT EPGEGPQQEV RRRDQFPLTR
     SRAIQECRSP VPPPAADPPE ARTKAPPGRK REPPAQAVRF LPWATPGLEG AAVPQTLEKN
     RAGPEAEKRL RRGPEEDGPW GPWDRRGARS QGKGRRARPT SPELESSDDS YVSAGEEPLE
     APVFEIPLQN VVVAPGADVL LKCIITANPP PQVSWHKDGS ALRSEGRLLL RAEGERHTLL
     LREARAADAG SYMATATNEL GQATCAASLT VRPGGSTSPF SSPITSDEEY LSPPEEFPEP
     GETWPRTPTM KPSPSQNRRS SDTGSKAPPT FKVSLMDQSV REGQDVIMSI RVQGEPKPVV
     SWLRNRQPVR PDQRRFAEEA EGGLCRLRIL AAERGDAGFY TCKAVNEYGA RQCEARLEVR
     AHPESRSLAV LAPLQDVDVG AGEMALFECL VAGPTDVEVD WLCRGRLLQP ALLKCKMHFD
     GRKCKLLLTS VHEDDSGVYT CKLSTAKDEL TCSARLTVRP SLAPLFTRLL EDVEVLEGRA
     ARFDCKISGT PPPVVTWTHF GCPMEESENL RLRQDGGLHS LHIAHVGSED EGLYAVSAVN
     THGQAHCSAQ LYVEEPRTAA SGPSSKLEKM PSIPEEPEQG ELERLSIPDF LRPLQDLEVG
     LAKEAMLECQ VTGLPYPTIS WFHNGHRIQS SDDRRMTQYR DVHRLVFPAV GPQHAGVYKS
     VIANKLGKAA CYAHLYVTDV VPGPPDGAPQ VVAVTGRMVT LTWNPPRSLD MAIDPDSLTY
     TVQHQVLGSD QWTALVTGLR EPGWAATGLR KGVQHIFRVL STTVKSSSKP SPPSEPVQLL
     EHGPTLEEAP AMLDKPDIVY VVEGQPASVT VTFNHVEAQV VWRSCRGALL EARAGVYELS
     QPDDDQYCLR ICRVSRRDMG ALTCTARNRH GTQTCSVTLE LAEAPRFESI MEDVEVGAGE
     TARFAVVVEG KPLPDIMWYK DEVLLTESSH VSFVYEENEC SLVVLSTGAQ DGGVYTCTAQ
     NLAGEVSCKA ELAVHSAQTA MEVEGVGEDE DHRGRRLSDF YDIHQEIGRG AFSYLRRIVE
     RSSGLEFAAK FIPSQAKPKA SARREARLLA RLQHDCVLYF HEAFERRRGL VIVTELCTEE
     LLERIARKPT VCESEIRAYM RQVLEGIHYL HQSHVLHLDV KPENLLVWDG AAGEQQVRIC
     DFGNAQELTP GEPQYCQYGT PEFVAPEIVN QSPVSGVTDI WPVGVVAFLC LTGISPFVGE
     NDRTTLMNIR NYNVAFEETT FLSLSREARG FLIKVLVQDR LRPTAEETLE HPWFKTQAKG
     AEVSTDHLKL FLSRRRWQRS QISYKCHLVL RPIPELLRAP PERVWVTMPR RPPPSGGLSS
     SSDSEEEELE ELPSVPRPLQ PEFSGSRVSL TDIPTEDEAL GTPETGAATP MDWQEQGRAP
     SQDQEAPSPE ALPSPGQEPA AGASPRRGEL RRGSSAESAL PRAGPRELGR GLHKAASVEL
     PQRRSPSPGA TRLARGGLGE GEYAQRLQAL RQRLLRGGPE DGKVSGLRGP LLESLGGRAR
     DPRMARAASS EAAPHHQPPL ENRGLQKSSS FSQGEAEPRG RHRRAGAPLE IPVARLGARR
     LQESPSLSAL SEAQPSSPAR PSAPKPSTPK SAEPSATTPS DAPQPPAPQP AQDKAPEPRP
     EPVRASKPAP PPQALQTLAL PLTPYAQIIQ SLQLSGHAQG PSQGPAAPPS EPKPHAAVFA
     RVASPPPGAP EKRVPSAGGP PVLAEKARVP TVPPRPGSSL SSSIENLESE AVFEAKFKRS
     RESPLSLGLR LLSRSRSEER GPFRGAEEED GIYRPSPAGT PLELVRRPER SRSVQDLRAV
     GEPGLVRRLS LSLSQRLRRT PPAQRHPAWE ARGGDGESSE GGSSARGSPV LAMRRRLSFT
     LERLSSRLQR SGSSEDSGGA SGRSTPLFGR LRRATSEGES LRRLGLPHNQ LAAQAGATTP
     SAESLGSEAS ATSGSSAPGE SRSRLRWGFS RPRKDKGLSP PNLSASVQEE LGHQYVRSES
     DFPPVFHIKL KDQVLLEGEA ATLLCLPAAC PAPHISWMKD KKSLRSEPSV IIVSCKDGRQ
     LLSIPRAGKR HAGLYECSAT NVLGSITSSC TVAVARVPGK LAPPEVPQTY QDTALVLWKP
     GDSRAPCTYT LERRVDGESV WHPVSSGIPD CYYNVTHLPV GVTVRFRVAC ANRAGQGPFS
     NSSEKVFVRG TQDSSAVPSA AHQEAPVTSR PARARPPDSP TSLAPPLAPA APTPPSVTVS
     PSSPPTPPSQ ALSSLKAVGP PPQTPPRRHR GLQAARPAEP TLPSTHVTPS EPKPFVLDTG
     TPIPASTPQG VKPVSSSTPV YVVTSFVSAP PAPEPPAPEP PPEPTKVTVQ SLSPAKEVVS
     SPGSSPRSSP RPEGTTLRQG PPQKPYTFLE EKARGRFGVV RACRENATGR TFVAKIVPYA
     AEGKRRVLQE YEVLRTLHHE RIMSLHEAYI TPRYLVLIAE SCGNRELLCG LSDRFRYSED
     DVATYMVQLL QGLDYLHGHH VLHLDIKPDN LLLAPDNALK IVDFGSAQPY NPQALRPLGH
     RTGTLEFMAP EMVKGEPIGS ATDIWGAGVL TYIMLSGRSP FYEPDPQETE ARIVGGRFDA
     FQLYPNTSQS ATLFLRKVLS VHPWSRPSLQ DCLAHPWLQD AYLMKLRRQT LTFTTNRLKE
     FLGEQRRRRA EAATRHKVLL RSYPGGP
//
